

Isomorphic Labs to appoint Max Jaderberg as President

Colin Murdoch will transition to an advisory role on January 1, 2026

LONDON, 26 November, 2025 - Isomorphic Labs has announced the appointment of Max Jaderberg as President of the company effective 1 January 2026, transitioning from his current role as Isomorphic Labs' Chief AI Officer. Colin Murdoch will step down from his role as President following a successful tenure leading the company through its breakout phase. Colin will remain a close advisor to both incoming President, Max, and to Founder and CEO Sir Demis Hassabis.

Max Jaderberg was a founding member of the Isomorphic Labs team and has built the company's approach to AI from the ground-up, spearheading the development of an AI drug design engine that enables scientists to probe new chemical space, explore previously intractable targets, and design new drug candidates with greater pace and precision. As a member of the executive leadership team, he has also been instrumental in shaping the next phase of the company's growth. As President, Max will oversee the day-to-day operations of the business, working closely with Demis to pursue the company's mission to one day solve all disease.

"My personal mission and core driver has always been to see the positive impact of technology on humanity," said Max Jaderberg. "Over the past few years I've seen up close the possibilities our work at Iso opens up for drug discovery and ultimately for patients, and I care deeply about unlocking them. The next phase of our work is about realising the full potential of our AI drug design engine to drive the business forward, and transform drug discovery. I am excited to do this alongside Demis, and the world-class team at Isomorphic Labs."

During Colin's time as President, Isomorphic Labs expanded its strategic partnership with Novartis and raised \$600 million in its first external funding round. Under his leadership, the company has grown to over 300 employees including engineers, scientists and operational experts across London, Lausanne and Cambridge, MA, and has developed a generalisable drug design engine which unlocks new possibilities to transform drug discovery.

"As President, my goal was to lead this crucial scaling of the company: build an interdisciplinary team with deep expertise, secure the support of forward-thinking investors and partners, and lay the groundwork to allow our scientific and technical innovation to progress," said Colin Murdoch. "I am incredibly proud of everything we have achieved as a team at Isomorphic Labs so far. With this foundation in place, now is the

time for a new leader to drive the company through its next phase, and Max is the perfect person to do just that."

"Colin has done a fantastic job as President, and I'm pleased that he will continue to play a part in our progress in an advisory capacity. Having worked with Max for several years, I have witnessed first hand his AI leadership, entrepreneurial mindset and strategic, mission-driven approach," said Demis Hassabis. "I'm delighted to see him take up the leadership position as President, and push forward our bold mission, to one day solve all disease with the help of AI."

About Max Jaderberg, Isomorphic Labs

Max Jaderberg will transition from Chief AI Officer to President of Isomorphic Labs, effective January 1, 2026. The AI company was founded in 2021 to apply frontier AI and cutting-edge computational methods to advance drug design from first principles, aiming to massively accelerate the drug discovery process and build the future of medicine.

In his role of Chief AI Officer, he leads the research, development, and application of pioneering AI models for drug discovery, driving breakthrough research in algorithms and machine learning methods across multiple application domains.

Before Isomorphic Labs, Max led the Open-Ended Learning research team at DeepMind where he pioneered numerous AI algorithms, combining large-scale deep learning, reinforcement learning, and generative models to achieve world-leading results, notably with AlphaStar, Capture the Flag, and Spatial Transformer Networks. His contributions to the field of AI, which include advancing reinforcement learning and neural network optimisation, have amassed over 40K citations.

Earlier in his career, he was CEO and co-founder of Vision Factory, a company specialising in deep learning image recognition technology, which was acquired by Google DeepMind in 2014 after winning the Imagenet competition that year.

Max holds both an undergraduate degree in engineering science and a PhD from the University of Oxford's Visual Geometry Group, where he developed deep learning algorithms for image understanding. He is widely published in top journals, including Nature and Science. He also sits on the board of ARIA, supporting the UK's tech and science ecosystem. Max, together with the team at Isomorphic Labs are committed to combining breakthrough machine learning with computational biology to unlock deeper scientific insights, faster breakthroughs, and life-changing medicines, with the ultimate mission to solve all disease.

About Isomorphic Labs

Isomorphic Labs was founded in 2021, with a mission to transform drug discovery with the power of artificial intelligence, ushering in a new era of biomedical breakthroughs. Isomorphic Labs is led by AI pioneer Sir Demis Hassabis, and its founding was built on the Nobel-winning AI breakthrough, AlphaFold. Isomorphic Labs, together with Google DeepMind, developed and released AlphaFold 3 in May 2024, a revolutionary AI model that can predict the structure and interactions of all of life's molecules with unprecedented accuracy. Isomorphic Labs has built a world-leading AI drug design engine comprising foundational AI models that are capable of working across multiple therapeutic areas and drug modalities. The company is continually innovating on model architecture and developing cutting-edge capabilities to advance drug design. Isomorphic Labs is headquartered in London and has office locations in Lausanne, Switzerland and Cambridge, Massachusetts. Isomorphic Labs is advancing a broad and ambitious drug design portfolio through partnered programs and wholly-owned internal programs. For more information, go to www.isomorphiclabs.com and follow us on [LinkedIn](#) and [X](#). For Media enquiries press@isomorphiclabs.com